Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 78 of the 79 references it cites were found in a registry or an index.

Midostaurin: a magic bullet that blocks mast cell expansion and activation

Open access

Abstract

Clinically relevant features in patients with systemic mastocytosis (SM) include the cosmetic burden of lesional skin, mediator-related symptoms, and organ damage resulting from mast cell (MC) infiltration in advanced forms of SM. Regardless of the SM variant, expansion of neoplastic MC in the skin and other organs is triggered by mutant forms of KIT, the most prevalent being D816V. Activation of MC with subsequent release of chemical mediators is often caused by IgE-dependent mechanisms in these patients. Midostaurin, also known as PKC412, blocks the kinase activity of wild-type KIT and KIT D816V, counteracts KIT-dependent growth of neoplastic MC, and inhibits IgE-dependent mediator secretion. Based on this activity-profile, the drug has been used for treatment of patients with advanced SM. Indeed, encouraging results have been obtained with the drug in a recent multi-center phase II trial in patients with advanced SM, with an overall response rate of 60% and a substantial decrease in the burden of neoplastic MC in various organs. Moreover, midostaurin improved the overall survival and relapse-free survival in patients with advanced SM compared with historical controls. In addition, midostaurin was found to improve mediator-related symptoms and quality of life, suggesting that the drug may also be useful in patients with indolent SM suffering from mediator-related symptoms resistant to conventional therapies or those with MC activation syndromes. Ongoing and future studies will determine the actual value of midostaurin-induced MC depletion and MC deactivation in these additional indications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdx290

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 79 references

Research works printed but not linked: 1

  1. Van Anrooij, 2016, Midostaurin (PKC412) in indolent systemic mastocytosis: a phase 2 trial, EHA Learning Center

Cited by

See all 85

Metadata

Authors
Valent, P., Akin, C., Hartmann, K., George, T. I., Sotlar, K., Peter, B., Gleixner, K. V., Blatt, K., Sperr, W. R., Manley, P. W., Hermine, O., Kluin-Nelemans, H. C., Arock, M., Horny, H.-P., Reiter, A., & Gotlib, J.
Affiliations
  • Ludwig Boltzmann Institute for Hematology and Oncology (AT)
  • University of Michigan (US)
  • University of Lübeck (DE)
  • University of New Mexico (US)
  • Paracelsus Medical University (AT)
  • Novartis (Switzerland) (CH)
  • Sorbonne Paris Cité (FR)
  • Centre National de la Recherche Scientifique (FR)
  • Pathologisches Institut (DE)
  • Heidelberg University (DE)
  • Stanford Cancer Institute (US)
Corresponding author
Valent, P.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2017-10
Volume
28
Issue
10
Pages
2367-2376
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2753355630
Cited by
79
References
79
Citations by year
2026: 4 · 2025: 4 · 2024: 4 · 2023: 13 · 2022: 8 · 2021: 14 · 2020: 11 · 2019: 15 · 2018: 5
FWCI
0.87
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
  • PubMed Central (acceptedVersion)
  • edoc (University of Basel) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
Funders
Austrian Science Fund (F4704-B20)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
  • Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
Keywords
midostaurin, systemic mastocytosis, KIT D816V mutation, mast cell activation, tyrosine kinase inhibitors, mast cell degranulation, mast cell activation syndrome, indolent systemic mastocytosis, survival outcomes
MeSH terms
Antineoplastic Agents, Humans, Mast Cells, Multicenter Studies as Topic, Clinical Trials, Phase II as Topic, Drug Resistance, Neoplasm, Staurosporine, Mastocytosis, Systemic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Midostaurin: a magic bullet that blocks mast cell expansion and activation. https://app.cochat.ai/papers/10.1093/annonc/mdx290
The paper
Valent, P., Akin, C., Hartmann, K., George, T. I., Sotlar, K., Peter, B., Gleixner, K. V., Blatt, K., Sperr, W. R., Manley, P. W., Hermine, O., Kluin-Nelemans, H. C., Arock, M., Horny, H.-P., Reiter, A., & Gotlib, J. (2017). Midostaurin: a magic bullet that blocks mast cell expansion and activation. Annals of Oncology. https://doi.org/10.1093/annonc/mdx290

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.